

# Divaluce®

Modified Sodium Hyaluronate Gel for Injection with Lidocaine

Shining Confidence **DIVALUCE**

# 01 Product story



## Brand story

**DIVALUCE** is a compound Italian word which add DIVA (Goddess) and LUCE (Light) together.

It contains meaning that woman's beauty like the light of a goddess.



Soft



Medium



Hard

## History










**DIVALUCE** is a Dermal filler that contains 20 years of Hyaluronic acid manufacturing know-how. Yooyoung Pharmaceutical company was the first hyaluronic acid manufacturing company in Korea in 1997 and has accumulated many years of technology.

1981	Established in 1981
1997	Approved KFDA-Manufacturer of the first Hyaluronic acid formula in Korea
2011	Approved Hyaluronic acid prefilled syringe line in Japan
2019	Approved by MFDS(Korea) for DIVALUCE Approved ISO 13485 for DIVALUCE
2021	Approved in Guatemala
2022	Approved in Uzbekistan, Taiwan and Thailand
2023	Approved in Philippines, Colombia and China

**DIVALUCE** is manufactured by MFDS guideline and high HA technology manufacturing process.

# 02 Series




Series	Soft	Medium	Hard
Product			
Gel type			
HA Structure (SEM)			
Indication	Fine lines (Wrinkles and folds)	Deeper lines (Wrinkles and folds)	Volume and facial contouring
Needle Size	29G	27G	25G
HA concentration	20mg/ml		
Lidocaine content	0.3%		

- Selectively injects into various areas by series.
- Uniform particle structure for smooth injection and consistent effect.
- All series contain lidocaine, reducing discomfort caused by pain.

# 03 Technology


## HIVE Technology Hybrid Technology Improving Viscosity Elasticity

Great Viscosity and elasticity comes from Yooyoung's specialised HIVE™ Technology which looks like Honeycomb.




### General

Unequal coupling by general cross linking.




### DIVALUCE

Homogeneous coupling by HIVE™ cross linking.



## High elasticity and viscosity

	★ Soft
	★ Medium
	★ Hard
Product R	● Product R-1
	● Product R-2
	● Product R-3
Product N	● Product N-1
	● Product N-2
	● Product N-3



Ref. Our Technology Research Institute measurement data

# 04 Safety


## Safety Data

This series have increased safety by managing BDDE residue and low Endotoxin Level. Minimize future occurrence of Inflammation and Allergic Reaction.

Contents	DIVALUCE	Product A	Product B	Product C
Endotoxin(EU/ml)	<0.2	<0.5	<0.5	<0.2
BDDE(ppm)	<0.5	<0.5	<2	<2
PH	7.0	7.0	7.2	7.36

## Excellent in vivo safety

DIVALUCE have proven to be safe by compatible with tissues around the skin after injection.



- Experiment animal : SKH1 hairless female mouse.
- The Change of filler volume (PrimosLITE Topography with software PRIMOS 5.8).  
Ref. Property and pre-clinical evaluation of YYD701-2(No. 16-0064)

## High quality Ingredients

DIVALUCE only uses proven hyaluronic acid and Lidocaine raw material that registered to EDQM (European Directorate for the Quality of Medicines).

# 05 Clinical Result

DIVALUCE Series have checked the Long duration through a 24-week animal experiment.

## Low Swelling & Long Duration





Figure. 3D representation as photo simulation(with Software PRIMOS 5.8)

\*P=0.027




Ref. Property and pre-clinical evaluation of YYD701-2(No. 16-0064)

### Clinical trial-WSRS (24 weeks)

#### WSRS evaluate

Most of evaluators satisfied with wrinkle improvement after procedure.




- Improvement : Decrease more than 1 grade from the baseline

### Clinical trial-GAIS (24 weeks)

#### GAIS evaluate

The Global Aesthetic Improvement Scale which evaluate patients satisfaction rate of appearance, Most of patients satisfied with the procedure.



- The subject assessed the degree of appearance improvement by GAIS at the 24 weeks session.
- 1(Worse)~+3(Very much improved)

Ref. Clinical study report(Protocol No. YYP-YYD701\_001)





